Gabriel S Macedo

Dr. Gabriel S Macedo


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Genetics and Molecular Biology
Verified
Journal Article
Open access
PDF file
GMGabriel S Macedo
Gabriel S Macedo
BABarbara Alemar
Barbara Alemar
PAPatricia Ashton-Prolla
Patricia Ashton-Prolla
Germline mutations in BRCA1 and BRCA2 (BRCA) genes confer high risk of developing cancer, especially breast and ovarian tumors. Since the cloning of these tumor suppressor genes over two decades ago, a significant amount of research has been done. Most recently, monoallelic loss-of-function mutations in PALB2 have also been shown to increase the risk of breast cancer. The identification of BRCA1, BRCA2 and PALB2 as proteins involved in DNA double-strand break repair by homologous recombination and of the impact of complete loss of BRCA1 or BRCA2 within tumors have allowed the development of novel therapeutic approaches for patients with germline or somatic mutations in said genes. Despite the advances, especially in the clinical use of PARP inhibitors, key gaps remain. Now, new roles for BRCA1 and BRCA2 are emerging and old concepts, such as the classical two-hit hypothesis for tumor suppression, have been questioned, at least for some BRCA functions. Here aspects regarding cancer predisposition, cellular functions, histological and genomic findings in BRCA and PALB2-related tumors will be presented, in addition to an up-to-date review of the evolution and challenges in the development and clinical use of PARP inhibitors.

9 October 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GMGabriel S Macedo
Gabriel S Macedo
LMLeonardo Lisbôa da Motta
Leonardo Lisbôa da Motta
JGJuliana Giacomazzi
Juliana Giacomazzi
CNCristina B. O. Netto
Cristina B. O. Netto
VMVanusa Manfredini
Vanusa Manfredini
PAPatricia Ashton-Prolla
Patricia Ashton-Prolla
Germline mutations in TP53 are the underlying defect of Li-Fraumeni Syndrome (LFS) and Li-Fraumeni-like (LFL) Syndrome, autosomal dominant disorders characterized by predisposition to multiple early onset cancers. In Brazil, a variant form of LFS/LFL is commonly detected because of the high prevalence of a founder mutation at codon 337 in TP53 (p.R337H). The p53 protein exerts multiple roles in the regulation of oxidative metabolism and cellular anti-oxidant defense systems. Herein, we analyzed the redox parameters in blood samples from p.R337H mutation carriers (C, n = 17) and non-carriers (NC, n = 17). We identified a significant increase in erythrocyte GPx activity and in plasma carbonyl content,an indicator of protein oxidative damage, in mutation carriers compared to non-carriers (P = 0.048 and P = 0.035, respectively). Mutation carriers also showed a four-fold increase in plasma malondialdehyde levels, indicating increased lipid peroxidation (NC = 40.20±0.71, C = 160.5±0.88, P<0.0001). Finally, carriers showed increased total antioxidant status but a decrease in plasma ascorbic acid content. The observed imbalance could be associated with deregulated cell bioenergetics and/or with increased inflammatory stress, two effects that may result from loss of wild-type p53 function. These findings provide the first evidence that oxidative damage occurs in carriers of a germline TP53 mutation, and these may have important implications regarding our understanding of the mechanisms responsible for germline TP53 p.R337H mutation-associated carcinogenesis.

11 August 2022 in Diversity
Verified
Journal Article
Open access
PDF file
MFMarina O. Favarini
Marina O. Favarini
TSTaiz L. L. Simão
Taiz L. L. Simão
GMGabriel S Macedo
Gabriel S Macedo
FGFabrício S. Garcez
Fabrício S. Garcez
LOLARISSA Rosa de OLIVEIRA
LARISSA Rosa de OLIVEIRA
EEEDUARDO EDUARDO EIZIRIK
EDUARDO EDUARDO EIZIRIK
The canid genus Lycalopex comprises six recently diversified South American species whose evolutionary relationships have been remarkably challenging to resolve. We analyzed 6000 bp of mitochondrial DNA (mtDNA) from 55 Lycalopex individuals (L. sechurae = 4, L. culpaeus = 7, L.griseus = 8, L.gymnocercus = 17, L.vetulus = 13 and L. fulvipes = 6), and nine specimens from the closely related species Cerdocyon thous, Chrysocyon brachyurus and Speothos venaticus, to reconstruct their phylogenetic relationships, estimate the support for species-level monophyly, and date their divergences. In addition, we also sequenced seven nuclear segments from the same taxa. Three different phylogenetic approaches converged on the same mitochondrial topology with strong support for most nodes. All species were confirmed to be monophyletic for mtDNA, except for one intriguing case in which two L. vetulus individuals carried L. gymnocercus haplotypes, potentially implying a case of interspecies admixture. L. vetulus was the first species to diverge (ca. 1.2 Mya), followed by L. sechurae and then L. gymnocercus. The most internal group comprised L. griseus and the sister-species L. culpaeus and L. fulvipes, which diverged around 430,000 years ago in southern Argentina or Chile. The analysis of nuclear markers revealed several examples of intra-specific variation coupled with lack of species monophyly, consistent with pervasive incomplete lineage sorting and/or hybridization in this recent radiation. Our results provide robust mitochondrial resolution of this challenging radiation, and illustrate the difficulty of attaining similar success with traditional nuclear markers.

23 May 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
MRMahira L. Rosa
Mahira L. Rosa
CBCláudia Bordignon
Cláudia Bordignon
JSJaqueline Schuch
Jaqueline Schuch
ABAngélica C. Baumont
Angélica C. Baumont
MBMarina Bessel
Marina Bessel
GMGabriel S Macedo
Gabriel S Macedo
Background/Objectives: Formalin-fixed paraffin-embedded tissue is widely used in pathology and molecular diagnostics, yet its variable quality can critically influence the accuracy of sequencing-based analyses. This study investigated pre-analytical and analytical factors that can affect exome sequencing performance in a Brazilian multicenter cohort of patients with breast cancer and prostate adenocarcinoma. Methods: Tumor samples were reviewed for diagnostic confirmation, and those with a minimum cellularity of 20% underwent DNA extraction, fluorometric quantification, fragmentation analysis, and exome sequencing. Pre-analytical parameters, including tumor content, DNA yield, and fragmentation profile, were recorded and correlated with sequencing results. Results: Only 36.7% of all analyzed samples (163/444) generated valid whole-exome sequencing data, corresponding to 55.6% of those that proceeded to sequencing (163/293). Although 94.5% of specimens met the minimum ≥20% cellularity threshold and 66.0% advanced to sequencing, a substantial proportion failed to yield usable exome data. Successful sequencing was associated with shorter storage durations (p < 0.001) and superior analytical parameters (higher autosomal coverage, longer read lengths, lower duplication rates, and higher target coverage at ≥500× and ≥100×; p < 0.001). Detailed fixation-related variables (e.g., formalin type, fixation time, ischemia time) were not consistently available across centers, representing a major limitation for causal interpretation of pre-analytical effects. Conclusions: Our study identified a high failure rate in sequencing archival tissue, highlighting the need to prioritize more recently collected specimens and refine standardized sample handling protocols to maintain DNA integrity. These improvements are essential for optimizing sequencing workflow performance and feasibility in real-world settings.

2 March 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JSJaqueline Schuch
Jaqueline Schuch
MBMariana R. Botton
Mariana R. Botton
ABAngélica C. De Baumont
Angélica C. De Baumont
GCGiovana Curzel
Giovana Curzel
NCNathan A. Cadore
Nathan A. Cadore
DRDaniela D. Rosa
Daniela D. Rosa
Introduction: Pharmacogenomic (PGx) variants can influence drug efficacy and safety, yet their prevalence in Latin American populations with cancer is underexplored. Our aim is to characterize the frequency and phenotypic distribution of actionable pharmacogenes in Brazilian patients with metastatic prostate cancer (MPC) and Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer (BC). Methods: This analysis included 452 patients (259 BC, 193 MPC) from a multicenter study across 19 Brazilian sites. Exome sequencing was performed, and PGx variants were analyzed using the Pharmacogenomics Clinical Annotation Tool (PharmCAT) following the Clinical Pharmacogenetics Implementation Consortium (CPIC®) guidelines. Genotypes, star alleles, and predicted phenotypes were reported for 15 clinically relevant pharmacogenes. Results: Actionable PGx phenotypes were detected in 99.33% of participants. The decreased-function ABCG2 rs2231142 T allele occurred at 8.96%, and the VKORC1 rs9923231 T allele at 32.63%. In SLCO1B1 , normal function predominated (63.11%), with 21.11% exhibiting decreased function. Normal metabolizer phenotypes were most frequent in CYP2C19 (45.35%), CYP2C9 (70.51%), and CYP3A4 (94.62%), whereas CYP2B6 was dominated by intermediate metabolizers (43.02%) and CYP3A5 by poor/intermediate metabolizers (93.79%). Normal diplotypes predominated in thiopurine-related genes ( NUDT15 : 92.92%; TPMT : 88.72%), although nonfunctional alleles were observed. In UGT1A1 , decreased-function alleles accounted for approximately 37% of participants. Clinically relevant DPYD and RYR1 variants were rare (<2.0%). Conclusion: Nearly all Brazilian patients with cancer carried at least one actionable PGx variant, highlighting the potential impact of PGx-guided therapy in oncology. These results underscore the value of integrating pharmacogenomic strategies into clinical practice in Brazil.

19 May 2026 in Genetics in Medicine Open
Verified
Journal Article
Open access
GMGabriel S Macedo
Gabriel S Macedo
JSJaqueline Bohrer Schuch
Jaqueline Bohrer Schuch
NCNathan Araujo Cadore
Nathan Araujo Cadore
ABAngélica Cerveira de Baumont
Angélica Cerveira de Baumont
GCGiovana Dallaio Curzel
Giovana Dallaio Curzel
DRDaniela Dornelles Rosa
Daniela Dornelles Rosa
The carcinogenesis of metastatic prostate cancer results from complex interactions between genetic and environmental factors. The genomic profiles of admixed populations, such as Brazilians, are still poorly explored, offering an opportunity to better understand the contribution of germline and somatic variants in these patients. In this multicenter study, 193 men with metastatic prostate cancer, who underwent matched tumor-normal exome sequencing, were enrolled from all five Brazilian macro-regions. Pathogenic and likely pathogenic germline variants in well-known prostate cancer genes were identified in only 5.7% of the patients, with one case (0.5%) harboring the TP53 p.(Arg337His) Brazilian founder variant. Variants in WNT9B, recently associated with familial prostate cancer, were identified in an additional 2.1% of the patients. In contrast to the germline data, somatic results were obtained in only a subset of patients. Regarding homologous recombination deficiency, 21.8% of patients harbored tumor loss-of-function variants in ATM, CDK12, BRCA2, and FANCA. Even with the low success rate of tumor samples, our data demonstrated that most loss-of-function variants in homologous recombination pathway genes occur as somatic events. Our findings also highlight the distinct germline genomic profile of the Brazilian population and underscore the challenges associated with performing comprehensive analyses on formalin-fixed paraffin-embedded samples.